Compare NSA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSA | PRCT |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2015 | 2021 |
| Metric | NSA | PRCT |
|---|---|---|
| Price | $29.55 | $34.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $33.44 | ★ $50.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $741,511,000.00 | $299,907,000.00 |
| Revenue This Year | N/A | $48.34 |
| Revenue Next Year | $1.27 | $29.35 |
| P/E Ratio | $48.68 | ★ N/A |
| Revenue Growth | N/A | ★ 50.07 |
| 52 Week Low | $28.02 | $27.80 |
| 52 Week High | $43.88 | $97.49 |
| Indicator | NSA | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 55.69 |
| Support Level | $29.56 | $29.04 |
| Resistance Level | $30.16 | $38.11 |
| Average True Range (ATR) | 0.63 | 1.83 |
| MACD | 0.13 | 0.76 |
| Stochastic Oscillator | 61.86 | 60.14 |
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.